Kappa-selenocarrageenan-induced apoptosis of multidrug-resistant human leukemia cell and its mechanism

Abstract

Abstract: AIM: To observe the apoptosis of K562 ADM cells induced by kappa-selenocarrageenan(KCS) and to explore its possible molecular mechanism. METHODS: MTT assay, Wright-Giemsa staining, DNA agarose gel electrophoresis and cell-cycle analysis were used for examining apoptosis in K562/ADM cells.Ex-pression of Fas, Bcl-2 and P53 proteins was measured with Flow cytometr(FCM). RP-PCR assay was employed to detect the expression of caspase-3 mRNA. RESULTS: KCS inhibited proliferation of K562/ADM cells.Morpho-logical typical changes of apoptosis were observed through light microscopy. DNA electrophoresis showed evident DNA fragmentation. Cell-cycle analysis indicated in-creased apoptotic cell population (Sub-G₁ proportion) as well as apparent S phase arrest. The expression of Fas an-tigens and caspase-3 mRNA significantly increased, and that of Bcl-2 antigens decreased sharply after application of KSC.There was no distinct change of the expression of P53 protein inK562/ADM cells treatedwith KSC.CONCLUSION: KSC induces apoptosis of K562/ADM cells via Fas-caspase-3 pathway.

Key words: leukemia, multi-drug resistance, kap-pa-selenocarrageenan, apoptosis, mechanism

CLC Number:

R973

ZHANG Zhe-wen, WEI Hu-lai, SU Hai-xiang, LIU Jian-min, HAO Chun-yan. Kappa-selenocarrageenan-induced apoptosis of multidrug-resistant human leukemia cell and its mechanism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(5): 505-508.

References

1 魏虎来.硒酸酯多糖和亚硒酸钠抗白血病效应的实验研究[J]. 兰州大学学报(自然科学版), 1996;32:122-5
2 Wei HL, Su HX, Yao XJ, Ma LF.Biological feature of human T-activated killer cells[J]. Chin JCancer Res, 1999;11:111-4
3 李尹雄.核酸的分离与纯化[A]. 见:卢圣栋, 主编.现代分子生物学实验技术[M]. 第 2版.北京:中国协和医科大学出版社, 1999:107-8
4 Boffa LC, Scarfi S, Maariani MR, Damonte G, Allfrey VC, Benatti U, et al.Dihydrotestoterone as selective cellular nucle-ar location vector for antigene peptide nucleic acid in prostatic carcinoma cells[J]. Cancer Res, 2000;60:2258-62
5 Aggarwal S, Gupta S.Increased apoptosis of T cell subsets in aging humans:altered expression of Fas (CD95), Fas ligand, Bcl -2, and Bax[J]. J Immunol, 1998;160:1627-37
6 Djebaili M, De Bock F, Baille V.Implication of P53 and caspase-3 in kainic acid but not in N-methyl-D-aspartic acid-induced apoptosis in organotypic hippocampal mouse cultures [J]. Neurosci Lett, 2002;327:1-4
7 Wei HL, Su HX, Bai DC, Zhao HS, Ge JG, Wang B, et al. Arsenic trioxide inhibits P-glycoprotein expression of multidrug-resistant human leukemia cells that overexpress mdr-1 gene and induces apoptosis[J]. Chin Med J, 2003;116:1644-8
8 吴兴, 陈峥嵘, 陈中伟.硒酸酯多糖诱导人骨肉瘤细胞凋亡作用的体外实验[J]. 肿瘤防治杂志, 2004;11:927-30
9 Caffrey PB, Frenkel GD.The development of drug resistance by tumor cells invitro isaccompanied by the development of sensi-tivity to selenite[J]. Cancer Lett, 1994;81:59-65
10 穆玉兰, 温泽清, 汤春生.微量元素与肿瘤耐药性关系的研究进展[J]. 中国癌症杂志, 2002;12:184-6
11 Liu SL, Shia DY, Liu GZ, Chen HL, Liu SJ, Hu YD.Roles of Se andNO in apoptosis of hepatoma cells[J]. Life Science, 2000;68:603-10
12 Mahadevan D, List AF.Targeting the multidrug resistance-1 transporter in AML:molecular regulation and therapeutic strate-gies[J]. Blood, 2004;104:1940-51
13 Johnstone RW, Cretney E, Smyth MJ.P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-in-dependent, cell death[J]. Blood, 1999;93:1075-85
14 Pallis M, Turzanski J, Higashi Y, Russell N.P-glycoprotein in acute myeloid leukaemia:therapeutic implicationsof itsasso-ciation with both a multidrug-resistant and an apoptosis-resistant phenotype[J]. Leuk Lymphoma, 2002;43:1221-8

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[3]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[4]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[5]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[6]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[7]	ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang. Progress on the pathological mechanism and treatment of frostbite [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
[8]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[9]	LI Xinyu, HUANG Xin. State of clinical application of meloxicam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
[10]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[11]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[12]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[13]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[14]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[15]	SHAO Mingkun, LIU Rong, SUN Pin, GUAN Shui, LIAO Bingcan, LI Sha, CONG Tao, LIANG Kai, MA Hui, SUN Changkai. Human body networks mechanisms of melatonin and its clinical applications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1031-1040.